Table 1. Patient Characteristics.
| Characteristic | No. (%) | |
|---|---|---|
| SCLC (n = 239) | NSCLC (n = 321) | |
| Age, median (IQR), y | 68 (60-73) | 67 (61-75) |
| Sex | ||
| Female | 32 (13.4) | 60 (18.7) |
| Male | 207 (86.6) | 261 (81.3) |
| BMI, median (IQR) | 23.7 (21.4-25.8) | 22.7 (20.8-25.0) |
| Hypertension | ||
| No | 124 (51.9) | 187 (58.3) |
| Yes | 115 (48.1) | 134 (41.7) |
| Diabetes | ||
| No | 170 (71.1) | 246 (76.6) |
| Yes | 69 (28.9) | 75 (23.4) |
| ECOG performance status | ||
| 0 | 23 (9.6) | 46 (14.3) |
| 1 | 208 (87.0) | 262 (81.6) |
| 2 | 8 (3.3) | 13 (4.1) |
| Cardiovascular disease | ||
| Atrial fibrillation | 3 (1.3) | 8 (2.5) |
| Valvular heart disease | 1 (0.4) | 1 (0.3) |
| Coronary artery disease | 23 (9.6) | 25 (7.8) |
| Complete atrioventricular block | 1 (0.4) | 0 |
| Stroke | 12 (5.0) | 9 (2.8) |
| Peripheral vascular disease | 3 (1.3) | 5 (1.6) |
| None | 196 (82.0) | 273 (85.0) |
| Coronary artery calcification | ||
| No | 50 (20.9) | 63 (19.6) |
| Yes | 189 (79.1) | 258 (80.4) |
| CAC score, median (IQR) | 165.3 (3.9-712.1) | 108.7 (3.8-428.2) |
| No. of coronary arteries with calcification | ||
| 0 | 50 (20.9) | 63 (19.6) |
| 1 | 50 (20.9) | 64 (19.9) |
| 2 | 21 (8.8) | 38 (11.8) |
| 3 | 34 (14.2) | 51 (15.9) |
| 4 | 94 (39.3) | 98 (30.5) |
| Aortic valve calcification | ||
| No | 174 (72.8) | 236 (73.5) |
| Yes | 65 (27.2) | 85 (26.5) |
| Mitral valve calcification | ||
| No | 226 (94.6) | 294 (91.6) |
| Yes | 13 (5.4) | 27 (8.4) |
| Tobacco use | ||
| Never | 31 (13.0) | 75 (23.4) |
| Current | 54 (22.6) | 57 (17.8) |
| Former | 154 (64.4) | 189 (58.9) |
| Pack-years, median (IQR)a | 40 (25-50) | 40 (27-50) |
| Alcohol use | ||
| Never | 81 (33.9) | 116 (36.1) |
| Current | 69 (28.9) | 96 (29.9) |
| Former | 89 (37.2) | 109 (34.0) |
| Stage | ||
| I-II | 33 (13.8) | 18 (5.6) |
| IIIA | 70 (29.3) | 89 (27.7) |
| IIIB | 84 (35.1) | 137 (42.7) |
| IIIC | 52 (21.8) | 77 (24.0) |
| Chemotherapy regimen | ||
| Etoposide + carboplatin | 102 (42.7) | 0 |
| Etoposide + cisplatin | 137 (57.3) | 0 |
| Paclitaxel + carboplatin | 0 | 291 (90.7) |
| Others | 0 | 30 (9.3) |
| Maintenance IO agent | ||
| None | 0 | 254 (79.1) |
| Durvalumab | 0 | 50 (15.6) |
| Pembrolizumab/nivolumab | 0 | 17 (5.3) |
| RT dose, median (IQR) | 60 (54.0-60.8) | 63 (60.0-64.5) |
| RT fraction, median (IQR) | 30 (30-30) | 30 (30-30) |
| RT modality | ||
| 3D-CRT | 116 (48.5) | 110 (34.3) |
| IMRT | 123 (51.5) | 211 (65.7) |
Abbreviations: 3D-CRT, 3-dimensional conformal radiotherapy; BMI, body mass index, calculated as weight in kilograms divided by height in meters squared; CAC, coronary artery calcium; CVD, cardiovascular disease; ECOG, Eastern Cooperative Oncology Group; IMRT, intensity-modulated radiotherapy; IO, immuno-oncology; NSCLC, non–small cell lung cancer; RT, radiotherapy; SCLC, small cell lung cancer; WHO, World Health Organization.
a
Estimated among patients with history of tobacco use.